To include your compound in the COVID-19 Resource Center, submit it here.

Celgene falls after lowering 2020 guidance

Celgene Corp. (NASDAQ:CELG) fell $19.57 (16%) to $99.99 on Thursday after announcing 3Q17 earnings and lowering its 2020 revenue guidance to $19-$20 billion from $21 billion. The drop equated to a $15 billion loss of market cap.

On its

Read the full 389 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers